Please login to the form below
Perjeta
This page shows the latest Perjeta news and features for those working in and with pharma, biotech and healthcare.
Roche preps new Kadcyla filings after phase 3 trial win
Neoadjuvant therapy is given with the intention of achieving a cure for patients with early-stage cancer, and Herceptin and follow-up HER2 drug Perjeta (pertuzumab) have been approved for this ... With Herceptin and follow-up Perjeta (pertuzumab) already
Latest news
-
Ocrevus surge keeps Roche smiling in Q3
However, the performance of Ocrevus and other drugs such as HER2 breast cancer therapy Perjeta (pertuzumab) and lung cancer therapy Alecensa (alectinib) – plus a strong showing in Asia-Pacific markets led
-
Daiichi-Sankyo takes rival to Roche’s Kadcyla into phase 3
mate Perjeta (pertuzumab).
-
Daily Brief: Biosimilar Herceptin can't make Perjeta cost effective and more
Herceptin biosimilars can’t make Perjeta cost effective, says NICE. NICE has once again rejected Roche’s HER2-positive breast cancer drug Perjeta for treating patients after surgery in those who ... NICE already recommends Perjeta with trastuzumab
-
Daily Brief: Theresa May and the diabetes sensor, Biosimilars hit Roche in Europe, Gilead CEO to step down
Perjeta sales continued to grow, specifically in the metastatic and neoadjuvant settings, rising to 1.3bn swiss francs in global sales.
-
CHMP backs first-line use for AZ’s Tagrisso in lung cancer
Roche picked up an important new approval recommendation for its HER2-targeting drug Perjeta (pertuzumab) as an adjuvant (post-surgery) treatment for HER2-positive breast cancer at high risk of recurrence ... The FDA approved adjuvant use of Perjeta last
More from news
Approximately 16 fully matching, plus 40 partially matching documents found.
Latest Intelligence
-
Back to the future
In 2013, Roche's biologics sales totalled $29.2bn. These were led by established oncology brands such as Avastin and MabThera/Rituxan, along with emerging breast cancer therapies such as Perjeta
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Engagement Expert, Healthcare Brand Communications, London
-
Excellent package
- Account Manager / Senior Account Manager
-
35, 000-40, 000
- Senior Account Director development role to Business Director, H...
-
Excellent package
-
Account Director
-
Competitive Salary Offered
-
Account Manager / Account Director
-
Competative
-
Senior Medical Writer
-
Salary TBC
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
- Senior Account Manager, Rare Diseases – Medical Communications, ...
-
Excellent package
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
-
Account Director, Medical Education
-
Salary TBC
-
Senior Account Manager
-
Competitive Salary Offered
-
Associate Director
-
£75, 000-90, 000
-
Medical Writer
-
Salary TBC
- Global Business Development Director – Health Education
-
excellent commission
-
Business Director
-
Competitive Salary Offered
Subscribe to our email news alerts
- Europe closer to biosimilar rule change, despite fierce resistance from pharma
- Novartis forges AI alliance with Oxford University
- FDA adcomm split on Sanofi’s type 1 diabetes drug
- Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
- Essential collaboration skills training for pharma and healthcare teams launched by Dovetail.
- Evenity back on track with FDA panel blessing in osteoporosis
PMHub
Hanson Zandi
Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...
Latest intelligence
- Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
- Healthcare leaders in the European Union should begin preparing for a breakthrough now...
- The UK’s new five-year pricing agreement
- Pharma has agreed to capped growth again - in exchange for uptake promises...
- Digital applications are transforming the market access landscape
- Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Quick links
Infographics
